Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

TERN-601

MARKETED

oral non-peptide small-molecule GLP-1 receptor agonist

4
graded findings
3
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 1Very low evidence 3

TERN-601 is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
TERN-601 MARKETED
Weight change Decrease
Low evidence

Oral non-peptide GLP-1RA (Terns Pharmaceuticals). Phase 1 SAD/MAD in healthy adults with obesity/overweight reported dose-dependent placebo-adjusted weight loss up to...

Terns Pharmaceuticals press Sept 2024; ADA 85th Scientific Sessions June 2025 Source
Full findingOral non-peptide GLP-1RA (Terns Pharmaceuticals). Phase 1 SAD/MAD in healthy adults with obesity/overweight reported dose-dependent placebo-adjusted weight loss up to 4.9% at 740 mg once daily over 28 days; 67% lost >=5% at top dose; >95% TEAEs mild. Phase 2 FALCON ongoing (12-week primary endpoint).
PopulationPhase 1 randomised double-blind placebo-controlled SAD/MAD in healthy adults with obesity/overweight; phase 2 FALCON ongoing
Fundingindustry - Terns (trial sponsor; inferred from registration trial)
Scope limitsno outcome data yet (ongoing)
Comparatorsplacebo
TERN-601 MARKETED
Weight change Decrease
Very low evidence

FALCON phase 2 (12-week topline): modest placebo-adjusted weight loss; program subsequently discontinued.

Terns Pharmaceuticals press release: Topline 12-week data from Phase 2 trial of oral GLP-... Source
PopulationFALCON phase 2 RCT, US multicentre, adults with obesity/overweight without diabetes; n=30 per active cohort + placebo; 12-wk topline
Fundingindustry - Terns
Scope limitsidentifier not fully verified; small sample (N~30)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
TERN-601 MARKETED
Safety signals Increase
Very low evidence

Reversible grade-3 liver enzyme elevations in the phase 2 follow-up period.

Terns Pharmaceuticals press release, 21 Oct 2025. Source
PopulationFALCON phase 2 (obesity/overweight); post-treatment follow-up
Fundingindustry - Terns (trial sponsor; inferred from registration trial)
Scope limitsidentifier not fully verified; small sample (N~30)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
TERN-601 MARKETED
Gastrointestinal tolerability Increase
Very low evidence

AE-related discontinuation in phase 2 higher than the favourable phase 1 profile suggested.

Terns Pharmaceuticals press release, 21 Oct 2025. Source
PopulationFALCON phase 2 (n=30 per active cohort + placebo)
Fundingindustry - Terns (trial sponsor; inferred from registration trial)
Scope limitsidentifier not fully verified; small sample (N~30)
Comparatorsplacebo